Turkish health company makes a $24 million biotechnology move in the US
Summary
Enlila Sağlık acquired 50.1% of U.S.-based Crescenta Biosciences for $24 million. The deal makes Enlila the main shareholder and gives it more control over strategic and management decisions. The company wants to accelerate Crescenta’s biotechnology solutions, research programs, and clinical work on a global scale. The transaction also highlights a Harvard University stake in Enlila and signals stronger cross-border growth ambitions in health technology and biotech.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected